Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Non-Current Deffered Revenue (2016 - 2023)

Theravance Biopharma (TBPH) has disclosed Non-Current Deffered Revenue for 11 consecutive years, with $175000.0 as the latest value for Q3 2023.

  • On a quarterly basis, Non-Current Deffered Revenue fell 12.06% to $175000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $175000.0, a 12.06% decrease, with the full-year FY2022 number at $192000.0, changed N/A from a year prior.
  • Non-Current Deffered Revenue was $175000.0 for Q3 2023 at Theravance Biopharma, down from $181000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $21.7 million in Q1 2019 to a low of $175000.0 in Q3 2023.
  • A 5-year average of $3.8 million and a median of $334000.0 in 2021 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: surged 101.32% in 2019, then tumbled 96.02% in 2021.
  • Theravance Biopharma's Non-Current Deffered Revenue stood at $6.8 million in 2019, then tumbled by 94.85% to $348000.0 in 2020, then decreased by 8.05% to $320000.0 in 2021, then crashed by 40.0% to $192000.0 in 2022, then dropped by 8.85% to $175000.0 in 2023.
  • Per Business Quant, the three most recent readings for TBPH's Non-Current Deffered Revenue are $175000.0 (Q3 2023), $181000.0 (Q2 2023), and $187000.0 (Q1 2023).